High epidermal growth factor receptor expression in metastatic colorectal cancer lymph nodes may be more prognostic of poor survival than in primary tumor

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 3, 2009, Pages 245-252

  Deng, Yanhong ^a   Kurland, Brenda F ^b   Wang, Jianping ^a   Bi, Jiong ^a   Li, Wen ^a   Rao, Sujata ^b   Lan, Ping ^a   Lin, Tongyu ^a   Lin, Edward ^b,c  

^a SUN YAT SEN UNIVERSITY   (China)

^b USA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Colorectal cancer; Epidermal growth factor receptor; Overall survival; Tissue microarray

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EVALUATION; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIMARY TUMOR; PROGNOSIS; PROTECTION; PROTEIN EXPRESSION; RISK FACTOR; TISSUE MICROARRAY; TUMOR LOCALIZATION; TUMOR VOLUME;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67749137646     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181891326     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol. 1995;13:2936-2943.
3. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696-2704.
4. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350: 2343-2351.
5. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247-257.
6. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001;344:1196- 1206.
7. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med. 1994;331:213-221.
8. Barrier A, Lemoine A, Boelle PY, et al. Colon cancer prognosis prediction by gene expression profiling. Oncogene. 2005;24:6155-6164.
9. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525-532.
10. Scartozzi M, Bearzi I, Berardi R, et al. Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options. Br J Cancer. 2007;97:92-97.
11. Nakamoto RH, Uetake H, Iida S, et al. Correlations between cyclooxygen-ase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer. Jpn J Clin Oncol. 2007;37:679-685.
12. Marsh S, McKay JA, Curran S, et al. Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis. Oncol Rep. 2002;9:231-234.
13. Li JQ, Miki H, Wu F, et al. Cyclin A correlates with carcinogenesis and metastasis, and p27(kip1) correlates with lymphatic invasion, in colorectal neoplasms. Hum Pathol. 2002;33:1006-1015.
14. Yamada H, Ichikawa W, Uetake H, et al. Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites. Clin Colorectal Cancer. 2001;1:169-173; discussion 174.
15. Komatsu K, Kobune-Fujiwara Y, Andoh A, et al. Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma. Br J Cancer. 2000;83:769-774.
16. Gupta N, Miyauchi S, Martindale RG, et al. Upregulation of the amino acid transporter ATB0, + (SLC6A14) in colorectal cancer and metastasis in humans. Biochim Biophys Acta. 2005;1741:215-223.
17. Knosel T, Yu Y, Stein U, et al. Overexpression of cyclooxygenase-2 correlates with chromosomal gain at the cyclooxygenase-2 locus and decreased patient survival in advanced colorectal carcinomas. Dis Colon Rectum. 2004;47:70-77.
18. Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal carcinomas. Science. 1989;244:207-211.
19. Tortola S, Steinert R, Hantschick M, et al. Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer. J Clin Oncol. 2001;19:2837-2843.
20. Zauber P, Sabbath-Solitare M, Marotta SP, et al. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. Mol Pathol. 2003;56:137-140.
21. Kong SL, Salto-Tellez M, Leong AP, et al. Discordant quantitative detection of putative biomarkers in nodal micrometastases of colorectal cancer: biological and clinical implications. J Clin Pathol. 2005;58:839-844.
22. Khorana AA, Ryan CK, Cox C, et al. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer. 2003;97:960-968.
23. Scartozzi M, Bearzi I, Berardi R, et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol. 2004;22:4772-4778.
24. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-1208.
25. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23:1803-1810.
26. Bralet MP, Paule B, Falissard B, et al. Immunohistochemical variability of epidermal growth factor receptor (EGFR) in liver metastases from colonic carcinomas. Histopathology. 2007;50:210-216.
27. Bibeau F, Boissiere-Michot F, Sabourin JC, et al. Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray. Virchows Arch. 2006;449:281-287.
28. McKay JA, Murray LJ, Curran S, et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer. 2002;38:2258-2264.
29. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21:2787-2799.
30. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer. 2001;92:1331-1346.
31. Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer. 1993;71:2454-2460.
32. Cunningham MP, Essapen S, Thomas H, et al. Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol. 2006;28:329-335.
33. Spano JP, Lagorce C, Atlan D, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol. 2005;16:102-108.
34. Kluftinger AM, Robinson BW, Quenville NF, et al. Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol. 1992;1:97-105.
35. Hemming AW, Davis NL, Kluftinger A, et al. Prognostic markers of colo-rectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol. 1992;51:147-152.
36. Galizia G, Lieto E, Ferraraccio F, et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol. 2006;13:823-835.
37. De Jong KP, Stellema R, Karrenbeld A, et al. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology. 1998;28:971-979.
38. Resnick MB, Routhier J, Konkin T, et al. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res. 2004;10:3069- 3075.
39. Azria D, Bibeau F, Barbier N, et al. Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer. BMC Cancer. 2005;5:62.
40. Komuta K, Koji T, Izumi S, et al. Expression of epidermal growth factor receptor messenger RNA in human colorectal carcinomas assessed by non-radioactive in-situ hybridization. Eur J Surg Oncol. 1995;21:269 -275.
41. Italiano A, Saint-Paul MC, Caroli-Bosc FX, et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann Oncol. 2005;16:1503-1507.
42. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66: 3992-3995.
43. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6:279 -286.
44. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007; 25:3230-3237.
45. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4: 844-847.
46. Atkins D, Reiffen KA, Tegtmeier CL, et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem. 2004;52:893-901.